CD8A and neoplasm: In preclinical models of PD-1 resistance, SAR445877 had a stronger tumor suppressive effect compared to pembrolizumab, increasing the ratio of CD8+/CD4+ T cells in tumors and significantly increasing the percentage of effector memory CD8+ T cells in tumors (215).